Genor Biopharma Holdings Limited (HK:6998) has released an update.
Genor Biopharma Holdings Limited is actively preparing for a significant merger involving the issuance of consideration shares and a new listing application. The company is also planning to increase its authorized share capital, change its name, and adopt a share option plan. While these developments could impact its stock value, investors are advised to be cautious as the merger’s completion is contingent upon several approvals.
For further insights into HK:6998 stock, check out TipRanks’ Stock Analysis page.